Your session is about to expire
← Back to Search
Other
Minimally-Invasive Procedure for Cancer
Phase 2
Waitlist Available
Led By Kaitlyn Kelly, MD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0-2.
Aged > 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 30 days of surgery
Awards & highlights
Study Summary
This trial is testing a new surgical technique that minimizes entry into the body and involves putting high concentrations of anticancer drugs directly into the abdomen. The goal is to improve short-term postoperative outcomes.
Eligible Conditions
- Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within 30 days of surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 30 days of surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of postoperative complications
Trial Design
1Treatment groups
Experimental Treatment
Group I: Minimally-Invasive ProcedureExperimental Treatment1 Intervention
single-arm study of laparoscopic cytoreduction and HIPEC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minimally-Invasive Procedure
2014
Completed Phase 2
~20
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,113 Previous Clinical Trials
1,519,852 Total Patients Enrolled
Kaitlyn Kelly, MDPrincipal InvestigatorUniversity of California, San Diego
1 Previous Clinical Trials
5 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger